Class 536/26.7 - The N-hetero ring is part of a bicyclic ring system

Subclass of Class 536 - Organic compounds -- part of the class 532-570 series
Definition: Compounds wherein the N-hetero ring is part of a bicyclic
No. of patents: 263
Last issue date: 05/17/2011

«First «Previous1 2 3 4 5 6 7 Next»Last»

Number	Title	Issue Date
7943758	3′-end nucleoside unit comprising phosphoramidite Methods of synthesizing nucleic acid oligomers on a solid-phase support having a 3′-end nucleoside unit introduced thereon-as represented by formula II: wherein of formula II re...	05/17/2011
7910726	Amidite for synthesizing modified nucleic acid and method for synthesizing modified nucleic acid The disclosure provides an excellent amidite for synthesizing a modified nucleic acid, which enables a protective group therein to be removed under a moderate condition, thereby stably producing a hydroxyl group-containing modified nucleic acid. The disclosure also ...	03/22/2011
7696345	Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hyb...	04/13/2010
7547776	Process for the production of fludarabine-phosphate lithium, sodium, potassium, calcium and magnesium salts and purification process for the production of fludarabine-phosphate and fludarabine-phosphate with a purity of at least 99.5% The present invention generally relates to a fludarabine-phosphate with a purity of at least 99.5%. ...	06/16/2009
7432248	Nucleoside derivatives for treating Hepatitis C virus infection Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein W, W1	10/07/2008
7429651	Fluorescent nucleobase conjugates having anionic linkers Provided are nucleotide-dye conjugates and related compounds in which a dye is linked to a nucleobase directly or indirectly by an anionic linker. The anionic character of the linker is provided by one or more anionic moieties which are present in the linker, such a...	09/30/2008
7427679	Precursors for two-step polynucleotide synthesis Precursors for use in the synthesis of polynucleotides are disclosed. The precursors include a heterocyclic base having an exocyclic amine group and a substituted or unsubstituted triaryl methyl protecting group bound to the exocyclic amine group. In particular embo...	09/23/2008
7425547	Nucleoside derivatives for treating hepatitis C virus infection Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula IB as follows: and pharmaceutically...	09/16/2008
7414031	5-nitro-nucleoside compounds for treating viral infections Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. ...	08/19/2008
7385050	Cleavable linker for polynucleotide synthesis Functionalized supports for polynucleotide synthesis are disclosed. The supports have linker moieties that are stable to conditions used in polynucleotide synthesis, but may be cleaved to release synthesized polynucleotides from the support. Methods of making the fu...	06/10/2008
7378401	Use of Fosfluridine Tidoxil (FT) for the treatment of intraepithelial proliferative diseases The present invention is directed to the systemic administration of Fosfluridine Tidoxil, (5-fluorouridine)-5′-phosphoric acid (3-dodecylmercapto-2-decyloxy)propylester or a salt thereof, for the treatment of intraepithelial proliferative diseases such as actinic ...	05/27/2008
7371852	Alkyl-linked nucleotide compositions Alkyl-linked nucleotide non-homogeneous solid supports and nucleotide affinity media comprising an alkyl-linked nucleotide are provided. The linker is generally a hydrophobic linker that can be a 3, 4, 5, 6, 7, 8, 9, 10, or a longer carbon chain. Also included in th...	05/13/2008
7368437	Bicyclic heterocycles, processes for their preparation and their use as herbicides and pharmaceutical agents Methods and compounds for inhibiting the enzymes adenosine monophosphate deaminase or adenoside deaminase are provided. Such methods and compounds are useful in agriculture, horticulture and/or pharmacology as, for example, active compounds for crop protection or ph...	05/06/2008
7368550	Phosphorus protecting groups Compounds having a phosphorus group structure of: wherein: R is alkyl, modified lower alkyl; and Ri and Ri are each independently H, alkyl, modified ...	05/06/2008
7339053	4′-C-substituted-2-haloadenosine derivative The present invention provides a 4′-C-substituted-2-haloadenosine derivative represented by the following formula [I], [II], or [III]: (wherein X represents a halogen atom, R1 represents an ethynyl group or a c...	03/04/2008
7339052	Phosphoramidite activator for oligonucleotide synthesis The present invention provides an improved phosphoramidite activator comprising a solution of 5-benzylmercaptotetrazole in acetonitrile and N-alkyimidazole. Further provided are improved methods of oligonucleotide synthesis wherein a phosphoramidite activator compri...	03/04/2008
7335470	Compilations of nucleic acids and arrays and methods of using them In one aspect the invention provides compilations of nucleic acids, articles of manufacture, e.g., arrays, and methods for the detection of chromosomal abnormalities, such as a chromosomal aneuploidies, deletions, amplifications, and the like, and the diagnosis or p...	02/26/2008
7323449	Thionucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase The present invention provides thionucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependen...	01/29/2008
7291606	Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging Novel compositions and methods are provided for identifying agents which affect chromosomal stability and aging. ...	11/06/2007
7273933	Methods for synthesis of oligonucleotides Improved methods for synthesis of oligonucleotides and other phosphorus-linked oligomers are disclosed. The methods include the use of aromatic solvents, alkyl aromatic solvents, halogenated aromatic solvents, halogenated alkyl aromatic solvents, or aromatic ether s...	09/25/2007
7270827	Multivalent streptococcal vaccine compositions and methods for use Compositions and methods for making and using therapeutic formulations of multivalent hybrid polypeptides comprising immunogenic peptides of M proteins from various different serotypes of group A streptococci and antibodies thereto are provided. Also provided are nu...	09/18/2007
7271258	Methods of synthesizing oligonucleotides using carbonate protecting groups and alpha-effect nucleophile deprotection The invention provides methods for synthesizing oligonucleotides using nucleoside monomers having carbonate protected hydroxyl groups that are deprotected with α-effect nucleophiles. The α-effect nucleophile irreversibly cleave the carbonate protecting groups whil...	09/18/2007
7244713	Nucleoside compounds for treating viral infections Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, T...	07/17/2007
7202223	Nucleoside compounds for treating viral infections Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, e...	04/10/2007
7199236	Process for the synthesis of oligomeric compounds Synthetic processes are provided wherein oligomeric compounds are prepared having phosphodiester, phosphorothioate, phosphorodithioate, or other covalent linkages. The oligomers have substantially reduced exocyclic adducts deriving from acrylonitrile or related cont...	04/03/2007
7169916	Chloral-free DCA in oligonucleotide synthesis A process of manufacturing oligonucleotides includes a 5′-deblocking step in which the 5-blocking group is removed with dichloroacetic acid that is essentially free of chloral. The process is useful for making oligonucleotides that are substantially free of chlora...	01/30/2007
7157434	Nucleoside compounds for treating viral infections Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, Y...	01/02/2007
7151089	Nucleoside compounds for treating viral infections Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, R...	12/19/2006
7144868	Nucleoside compounds for treating viral infections Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein, e...	12/05/2006
7138517	Sugar modified oligonucleotides Compositions and methods are provided for the treatment and diagnosis of diseases amenable to modulation of the production of selected proteins. In accordance with preferred embodiments, oligonucleotides and oligonucleotide analogs are provided which are specificall...	11/21/2006
7125855	Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase The present invention provides nucleoside compounds and certain derivatives thereof which are inhibitors of RNA-dependent RNA viral polymerase. These compounds are inhibitors of RNA-dependent RNA viral replication and are useful for the treatment of RNA-dependent RN...	10/24/2006
7119184	Oligonucleotides having A-DNA form and B-DNA form conformational geometry Modified oligonucleotides containing both A-form conformation geometry and B-from conformation geometry nucleotides are disclosed. The B-form geometry allows the oligonucleotide to serve as substrates for RNase H when bound to a target nucleic acid strand. The A-for...	10/10/2006
7112575	Energy-protective composition comprising adenosine phosphates Compositions comprising the nucleotides adenosine diphosphate and adenosine monophosphate, and their use for neutralizing effects of excess incident energy on the human body, particularly effects of ionizing radiation from nuclear or radiological energy sources, are...	09/26/2006
7101981	Bovine growth hormone recombinantly produced in Recombinant materials have been obtained which permit the production of bovine growth hormone in E. coli. ...	09/05/2006
7101993	Oligonucleotides containing 2′-O-modified purines Compounds are provided containing purine nucleotides that bear moieties X at the 2′ position thereof wherein X is R1—(R2)n; R1 is C3-C20 alkyl, C4-C20 alkenyl or C2	09/05/2006
7094768	Nucleoside derivatives for treating hepatitis C virus infection Disclosed are 6-hydroxyamino- or a 6-alkoxyamino-7-deazapurine-ribofuranose derivatives, salts, pharmaceutical compositions, and methods of use thereof for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. ...	08/22/2006
7081449	Pyrido[2,3-d]pyrimidine and pyrimido[4,5-d]pyrimidine nucleosides A purine nucleoside analog includes a pyrido[2,3-d]pyrimidine or a pyrimido[4,5-d]pyrimidine and further has a sugar moiety that is optionally modified at the C2′, C3′, C4′ and/or C5′ position. Particularly contemplated compounds also include prodrug forms o...	07/25/2006
7064112	Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist Adenosine receptor agonists, particularly an agonist which binds to the A3 adenosine receptor, are used for induction of production or secretion of G-CSF within the body, prevention or treatment of toxic side effects of a drug or prevention or treatment of leukopeni...	06/20/2006
7063850	Protective antigen of group A The present invention provides the discovery of a new Streptococcus protective antigen (herein designated Spa) which has been identified and isolated from Streptococci. Spa is a surface antigen distinct from M protein which evokes opsonic antibodies that are ...	06/20/2006
7045309	9-substituted adenine derivatives as prodrug regulators of cell and tissue function The present invention relates to 9-substituted adenine derivatives represented by formula (I) wherein W is selected from the group consisting of H, halogen, azido and amino group; X is selected from the group consistin...	05/16/2006

«First «Previous1 2 3 4 5 6 7 Next»Last»

PatentStorm

Did You Know...

PatentStorm News

Class 536/26.7 - The N-hetero ring is part of a bicyclic ring system